<DOC>
	<DOCNO>NCT01716533</DOCNO>
	<brief_summary>This study aim 1 ) evaluate C. difficile-specific immune response CDI patient 2 ) explore difference immune response patient CDI recurrence sustain clinical response .</brief_summary>
	<brief_title>Evaluation Immune Response Clostridium Difficile Adults With Clostridium Difficile Infection ( CDI )</brief_title>
	<detailed_description>Patients initial episode CDI follow CDI recurrence sustain clinical response . The subject allocate 2 group study end : - Recurrence Group : Subjects experience recurrence CDI clinical response antibiotic treatment treat initial CDI episode . - Sustained response Group : Subjects experience recurrence CDI clinical response antibiotic treatment treat initial CDI episode . This protocol amend twice improve recruitment subject study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Clostridium Infections</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol or/ subject receive assistance his/ legally acceptable representative ( LAR ) designate comply requirement protocol . A male female age 18 year old time enrolment . Written inform consent obtain subject/ LAR subject . A reasonable prognosis survival study period judge investigator . Outpatients , emergency room and/ hospitalized subject diagnose CDI symptom start maximum 14 day prior study enrolment . Subjects receive plan receive antibiotic treatment treat CDI episode . Concurrently participate plan participate another clinical study , time study period , subject expose investigational noninvestigational product . Previous CDI episode within previous 6 month study enrolment ( except ~25 % subject ) . Chronic diarrheal illness , limited , ulcerative colitis Crohn 's disease . Planned surgery CDI within 24 hour study entry . Previous vaccination Clostridium difficile . Having receive Clostridium difficile monoclonal antibody product ( ) within previous 3 month plan administration study period . Administration immunoglobulin within previous 3 month plan administration study period . Subject condition , opinion investigator , would jeopardize safety right subject participate study , would make unlikely subject complete study , would confound result study . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug within previous 6 month . Any confirm suspected immunosuppressive immunodeficient condition , base medical history . Family history congenital hereditary immunodeficiency . Major congenital defect .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Serological</keyword>
	<keyword>Adults</keyword>
	<keyword>Clostridium difficile</keyword>
	<keyword>Adult CDI patient</keyword>
</DOC>